Palatin Technologies is a biopharmaceutical company focused on the development of innovative therapies for a range of medical conditions, including sexual health disorders and other areas with unmet therapeutic needs
The company primarily works on peptide-based drug candidates, leveraging its proprietary technologies to create treatments that target specific physiological pathways. Palatin is committed to advancing its development programs through rigorous research and clinical trials, with the aim of providing effective solutions for patients and improving overall health outcomes.
Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions
The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Palatin Technologies' results from PL9643 MELODY-1 Phase 3 trial for dry eye disease. The co-primary endpoints and secondary endpoints did not reach statistical significance.
U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.52% to 38,770.83 while the NASDAQ fell 0.63% to 15,933.71. The S&P 500 also fell, dropping, 0.33% to 5,061.21.
Cosette Pharmaceuticals, Inc. (“Cosette”), a US-based specialty pharmaceutical company with a focus on women’s health and cardiovascular medicines, has completed the acquisition of Vyleesi® from Palatin Technologies, Inc. (NYSEPTN), which includes 5 Orange Book listed patents with protection up to 2041. Palatin and Cosette will ensure continued patient and healthcare professional access to Vyleesi® throughout the transition period.
Shares of Getaround, Inc. (NYSEGETR) rose sharply in pre-market trading after the company reported a year-over-year increase in third-quarter financial results.
